At ASMS 2026, mass spectrometry stakes its claim Sessions spanning chemoproteomics, AI-driven proteomics, biotherapeutic characterization, single-cell omics, and spatial multiomics all pointed toward mass spectrometry’s growing role in drug discovery and development. Written byAndrea Corona

https://www.drugdiscoverynews.com/at-asms-2026-mass-spectrometry-stakes-its-claim-17280 The 74th annual conference on Mass Spectrometry and Allied Topics ran June 1–5 at the San Diego Convention Center, bringing together researchers across academia, industry, and government for four days of oral sessions, poster presentations, workshops, and exhibits. The program — spanning more than 40 concurrent oral sessions per day across topics from ion mobility instrumentation to clinical analysis, environmental contaminants, and cancer immunology — offered a cross-section of where mass spectrometry currently sits and where it is heading.